Current Treatment Options in Neurology

, Volume 13, Issue 4, pp 413–426 | Cite as

Medical Management of Patients With Brain Tumors

Neuro-oncology (Neoplasms)

Opinion statement

Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should be used in divided doses in the minimum amount required to control symptoms and should be tapered as quickly as possible. Some patients may require long-term steroid supplementation, and symptoms of adrenal insufficiency should be investigated with 8 am cortisol measurement and treated with appropriate repletion. (2) Seizures: Patients with brain tumors should receive antiepileptic drugs only if they have had seizures, and the drugs should be chosen to minimize cognitive effects and interactions with concurrently administered chemotherapy. Levetiracetam is an excellent choice for patients with partial seizures and is available both orally and parenterally. Lamotrigine is another reasonable choice but requires slow titration. (3) Venous thromboembolism: All brain tumor patients should receive perioperative venous thrombosis prophylaxis with compression boots and enoxaparin or dalteparin. Lifelong treatment with low molecular weight heparinoids or warfarin is required for those developing venous thromboembolism. (4) Other problems: Long-term survivors of brain tumors should be monitored indefinitely for cognitive problems, endocrine dysfunction, and development of secondary neoplasms. Modafinil can improve mood and attention impairments.

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol. 2008;9(9):884–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Wenger NS, Vespa PM. Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist. Oncologist. 2010;15 Suppl 1:43–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Wilson JF. Cancer care: a microcosm of the problems facing all of health care. Ann Intern Med. 2009;150(8):573–6.PubMedGoogle Scholar
  4. 4.
    Keating NL, Landrum MB, Rogers Jr SO, et al. Physician factors associated with discussions about end-of-life care. Cancer. 2010;116(4):998–1006.PubMedCrossRefGoogle Scholar
  5. 5.••
    Pace A, Metro G, Fabi A. Supportive care in neurooncology. Curr Opin Oncol 2010; 22(6):621–626.PubMedCrossRefGoogle Scholar
  6. 6.
    Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20(6):1337–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Watling CJ, Cairncross JG. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. J Neurosurg. 2002;97(1):224–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Vecht CJ, Hovestadt A, Verbiest HBC, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44:675–80.PubMedGoogle Scholar
  9. 9.
    Meyer G, Badenhoop K. Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin (Munich). 2003;98(5):266–70.CrossRefGoogle Scholar
  10. 10.
    Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol. 2003;63(3):263–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348(8):727–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time. .. nothing was working”. JAMA. 2007;298(10):1196–207.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee JW, Bromfield EB, Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med. 2008;359(17):1853.PubMedCrossRefGoogle Scholar
  17. 17.
    Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.PubMedGoogle Scholar
  18. 18.
    van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Mamon HJ, Wen PY, Burns AC, et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999;40(3):341–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 2004;1 Suppl 1:S10–7.PubMedGoogle Scholar
  21. 21.•
    Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71(9):665–669.PubMedCrossRefGoogle Scholar
  22. 22.
    Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137(11):889–903.PubMedGoogle Scholar
  25. 25.
    Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. 2001;7(5):326–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89(3):640–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol. 2010;23(6):592–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73(1):222–7.PubMedCrossRefGoogle Scholar
  31. 31.••
    Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8(2):221–227.PubMedCrossRefGoogle Scholar
  32. 32.
    Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 2008;10(3):355–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27(29):4889–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–505.PubMedCrossRefGoogle Scholar
  35. 35.
    Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004;5(6):511–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs. low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53(1):1–6.CrossRefGoogle Scholar
  37. 37.••
    Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8(9):1959–1965.PubMedCrossRefGoogle Scholar
  38. 38.
    Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999;8(2):139–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Triebel KL, Martin RC, Nabors LB, et al. Medical decision-making capacity in patients with malignant glioma. Neurology. 2009;73(24):2086–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Pelletier G, Verhoef MJ, Khatri N, et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57(1):41–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522–7.PubMedGoogle Scholar
  43. 43.
    Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Shaw EG, Rosdhal R, D’Agostino Jr RB, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Pruitt A, Dalmau J, Detre J, et al. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. Neurology. 2006;67(4):676–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Grimm SA, Yahalom J, Abrey LE, et al. Retinopathy in survivors of primary central nervous system lymphoma. Neurology. 2006;67(11):2060–2.PubMedCrossRefGoogle Scholar
  47. 47.
    Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Al-Mefty O, Topsakal C, Pravdenkova S, et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg. 2004;100(6):1002–13.PubMedCrossRefGoogle Scholar
  49. 49.•
    El-Jawahri A, Podgurski LM, Eichler AF, et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 2010; 28(2):305–310.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaal ECA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593–600.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations